Fact CheckerSign in

NCT05859191Recruiting

Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus

Study of Neonatal Immunoglobulin G (IgG) Fc Receptor (FcRn) Expression in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT): Implication in the Pathophysiology of Systemic Lupus

Source: ClinicalTrials.gov · Last updated 30 Apr 2026

Brief summary (registry, in English)

This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.

Status (registry)
Recruiting
Study type
Observational
Enrollment
50 (estimated)
First submitted
3 May 2023
Start date
21 Jul 2023
Primary completion date
Jul 2027
Lead sponsor
University Hospital, Tours
Diseases
Lupus (SLE)
NCT number
NCT05859191

What you commit to

  • Study type: Observational
  • Planned participants: 50
  • From 21 Jul 2023 to the primary completion date, Jul 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Main autoimmune disease other than lupus

Other

  • Patient under legal protection, guardianship or curators
  • Opposition to data processing

Who the study is looking for

  • Age ≥ 18 years
  • Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
  • Lupus patient, newly diagnosed or known, untreated or in relapse
  • Lupus patient considered stable by the treating practitioner
  • Requiring blood sampling for follow-up

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
University hospital
Coordinator of this site? Confirm its status
ToursFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.